Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer

Breast Cancer Research and Treatment

Volumn 38, Issue 1, 1996, Pages 27-39

  Schlom, Jeffrey ^a,c   Kantor, Judy ^a   Abrams, Scott ^a   Tsang, Kwong Y ^a   Panicali, Dennis ^b   Hamilton, J Michael ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Therion Biologics Corporation   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Carcinoembryonic antigen (CEA); Immunotherapy; Phase I trial; Recombinant vaccines; Vaccinia virus

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; RECOMBINANT VACCINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER MODEL; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; CONFERENCE PAPER; DRUG SAFETY; DRUG TARGETING; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOGENICITY; LUNG METASTASIS; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIMATE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CLINICAL TRIALS, PHASE I; FEMALE; HUMANS; IMMUNITY, CELLULAR; MICE; VACCINES, SYNTHETIC;

EID: 0030033054     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01803781     Document Type: Conference Paper

References (36)

1. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repairs after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994
2. Bernards R, Destree A, McKenzie S, Gordon E, Weinberg RA, Panicali D: Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 84:6854-6858, 1987
3. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54:1071-1076, 1994
4. Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA: A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 53: 3257-3261, 1993
5. Abe M, Kufe D: Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci USA 90:282-286, 1993
6. Barnd DL, Lan MS, Metzgar RS, Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86:7159-7163, 1989
7. Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G, Mancuso S, Frati L, Nuti M: Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 53:2457-2459, 1993
8. Hareuveni M, Gautier C, Kieny M-P, Wreschner D, Chambon P, Lathe R: Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA 87:9498-9502, 1990
9. Hareuveni M, Wreschner DH, Kieny M-P, Dott K, Gautier C, Tomasetto C, Keydar I, Chambon P, Lathe R: Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA). Vaccine 9:618-626, 1991
10. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J: Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 46:3118-3124, 1986
11. Longenecker BM, Reddish M, Koganty R, MacLean GD: Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus Detox adjuvant. Ann NY Acad Sci 690:276-291, 1993
12. MacLean GD, Reddish M, Koganty RR, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, Longeneckcr BM: Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 36:215-222, 1993
13. Robbins PF, Eggensperger D, Qi C-F, Schlom J: Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 53:892-897, 1993
14. Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE: Prognostic relevance of carcino-embryonic antigen and estrogen receptor status in breast cancer patients. Cancer 74:1575-1583, 1994
15. Bhattacharya-Chatterjee M, Foon KA, Kohler H: Anti-idiotpye monoclonal antibodies as vaccines for human cancer. Int Rev Immunol 7:289-302, 1991
16. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 84:1084-1091, 1992
17. Van der Bruggen P, Traversari C, Chomez P, Larquin C, DePlaen E, Van den Eynde B, Kunth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science 254; 1643-1647, 1991
18. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462, 1994
19. Ruby J, Ramsay A, Karupiah G, Ramshaw I: Recombinant virus vectors that coexpress cytokines - a new vaccine strategy. Vaccine Res 1:347-356, 1992
20. Schwartz RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065-1068, 1992
21. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102, 1992
22. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM: B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143:2714-2722, 1989
23. Salgaller ML, Bei R, Schlom J, Poole DJ, Robbins PF: Baculovirus recombinants expressing the human carcinoembryonic antigen gene. Cancer Res 53:2154-2161, 1993
24. Jenner E: An inquiry into the causes and effects of the variolae vacciniae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox. Sampson Low, London, 1978
25. World Health Organization. Declaration of global eradication of smallpox. Wkly Epidemiol Rec 55:145-152, 1980
26. Fenner F, Henderson DA, Arita I, Jezck Z, Ladnyi ID: Smallpox and its eradication. World Health Org, Geneva, 1988
27. Moss B: Vaccinia virus vectors. In: Ellis RW (ed) Vaccines: New Approaches to Immunological Problems. Butterworth-Heinemann, 1992, pp 369-511
28. Kaufman H, Schlom J, Kantor J: A rccombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 48:900-907, 1991
29. Fuchs C, Krapf F, Kern P, Hoferichter S, Jager W, Kalden JR: CEA-containing immune complexes in sera of patients with colorectal and breast cancer - analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 26:180-184, 1988
30. Abeyounis CJ, Wilhelm SA, Rittenhouse KW, Milgrom F: Is carcinoembryonic antigen an autoantigen? Transplan Proc 16:489-491, 1984
31. MacSween JM: The antigenicity of carcinoembryonic antigen in man. Int J Cancer 15:246-252, 1975
32. Steele G, Lahey S, Rodrick M, Ross D, Deasy J, Zamcheck N, Osteen R, Wilson R: Circulating immune complexes in patients with colorectal cancer. Am J Surg 145:549-553, 1983
33. Horan Hand P, Robbins PF, Salgaller ML, Poole DJ, Schlom J: Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol Immunother 36:65-75, 1993
34. Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, Kaufman H, Eggensperger D, Schlom J: Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 52:6917-6925, 1992
35. Hamilton JM, Chen AP, Nguyen B, Grem J, Abrams S, Chung Y, Kantor J, Phares JC, Bastian A, Brooks C, Morrison G, Allegra CJ, Schlom J: Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas [abstract]. ASCO Proc, 961, 1994
36. Tsang K, Zaremba S, Hamilton JM, Schlom J: Analysis of T-cell responses to carcinoembryonic antigen (CEA) in carcinoma patients following immunization with a recombinant vaccinia CEA vaccine. J Natl Cancer Inst 87:982-990, 1995